International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor

Vanerio, Gabriel

doi:10.1016/j.jstrokecerebrovasdis.2015.05.017

Cited by 14 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recently published study from Vanerio10 patients with AF showed that INR variability can be advantageously used to assess anticoagulation quality. Calculation of both CHA 2 DS 2 VASc and INR variability may facilitate mortality prediction in patients with AF receiving warfarin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis

Grzymala-Lubanski

Svensson²,

Renlund

et al. 2016

Heart

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…In a recent study in patients with AF, measuring INR variability in addition to TTR added information and increased the prognostic value compared with just TTR assessment 10. Also with INR variability, there are only limited data available in patients with MHV 11…”

Section: Introductionmentioning

confidence: 99%

Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis

Grzymala-Lubanski

Svensson²,

Renlund

et al. 2016

Heart

View full text Add to dashboard Cite

show abstract

“…As this study showed, the standard deviation (SD) of observed INR values (SD INR ) is an important index of the INR variability, reflecting INR fluctuations, either outside or within the therapeutic window. The variability of INR is an important factor associated with the anticoagulation effects of warfarin, which is related directly to prognosis in patients on warfarin therapy [8,24,25]. In this study, INR fluctuation was associated with the patient history of CHD, PAD, and diabetes mellitus, which suggested these comorbidities significantly impacted the stability of anticoagulation.…”

Section: Discussionmentioning

confidence: 65%

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry

Haifeng

Zhou

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

Background Several factors determine the efficacy of warfarin anticoagulation in patients with non-valvular atrial fibrillation (NVAF). This study aimed to use data from the Chinese Atrial Fibrillation Registry study to assess the control of anticoagulation therapy in Chinese patients with NVAF treated with warfarin. Material/Methods From the Chinese Atrial Fibrillation Registry study the anticoagulant use and dosing, the time in therapeutic range (TTR) of the international normalized ratio (INR), and standard deviation of the observed INR values (SD INR ), and their influencing factors were evaluated. Results The median INR and SD INR were 2.04 (IQR 1.71–2.41) and 0.50 (IQR, 0.35–0.69), respectively. The median TTR was 51.7% (IQR, 30.6–70.1%) and only 25.1% had a TTR ≥70%. Age was ≥70 years (OR, 0.72; 95% CI, 0.55–0.94; P=0.015), bleeding history (OR 0.48; 95% CI, 0.23–0.89; P=0.029), the use of a single drug (OR, 0.62; 95% CI, 0.42–0.92; P=0.016), more than drug (OR, 0.60; 95% CI, 0.41–0.88; P=0.009), and lack of assessment of bleeding risk (OR, 0.72; 95% CI, 0.54–0.97; P=0.033) were associated with TTR <70% (INR 2.0–3.0). Coronary heart disease (CHD) and peripheral artery disease (PAD) (OR, 0.69; 95% CI, 0.52–0.90; P=0.007) and diabetes mellitus (OR, 0.79; 95% CI, 0.62–0.99; P=0.044) were associated with increased variability in INR (SD INR ≥0.5). Conclusions In Chinese patients with NVAF, warfarin anticoagulation was associated with lower TTR and less stable anticoagulation than in current guidelines, and risk factors for reduced safety and efficacy were identified.

show abstract

“…При этом высокая вариабельность МНО сопровождается повышенным риском кровотечений и эмболических осложнений [52][53][54]. По данным британского регистра General Practice Research Database, включавшего 18 113 больных с ФП, сокращение времени нахождения МНО в терапевтических границах менее 70 % приводило к повышению риска развития инсульта и смерти больных [55].…”

Section: клинические семинары §unclassified

The Nephrological Aspects of the Use of Rivaroxaban and Other Direct Peroral Anticoagulants in Non-Valvular Atrial Fibrillation

Батюшин

2019

Kardiologiia

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a powerful cardiovascular risk factor, its presence is accompanied by an increased risk of hospitalization for exacerbation of chronic heart failure (CHF), adverse outcomes in myocardial infarction, and cardiovascular mortality. Among the adverse events, an increased risk of atrial fibrillation (AF) should be noted. This article contains discussion of current approaches to the treatment of AF in patients with different stages of CKD, data on benefits of certain direct oral anticoagulants, as well as comparative characteristics of therapy with direct oral anticoagulants and warfarin. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants, which determine the features of therapy in CKD, are also considered.

show abstract

International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor

Cited by 14 publications

References 21 publications

Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis

Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry

The Nephrological Aspects of the Use of Rivaroxaban and Other Direct Peroral Anticoagulants in Non-Valvular Atrial Fibrillation

Contact Info

Product

Resources

About